Remembering Our Chairman Emeritus, Dr. John Mendelsohn (1936-2019)
Posted: Tuesday, January 08, 2019
Remembering Dr John Mendelsohn
It is with great sadness, that we announce the passing of our Chairman Emeritus of WIN Consortium (WIN), Dr John Mendelsohn yesterday evening, January 7th, 2019 at the age of 82.
Dr Mendelsohn, M.D., President Emeritus of the University of Texas, MD Anderson Cancer Center was a founding father of the WIN Consortium, a brilliant scientist and visionary, optimist and a truly inspirational leader.
With others, his vision was to create a not-for-profit clinical research organization that advocates global collaboration, sharing information in order to bring the latest innovations in precision cancer medicine in treating diverse patient populations.
WIN remains part of his international lifelong legacy and achievements to improve personalized cancer care to the patient and we honor his memory in helping to continue to build WIN to where it is today. WIN, presently, a consortium of 40 members from 21 countries across 4 continents with the participation and expertise from the major stakeholders in precision oncology, academia, industry, not-for-profits and payors.
WIN is indebted to his knowledge, expertise, mentoring, time and friendship and we have been blessed to have him as our founding Chairman; he will be deeply missed.
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 40 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.